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will exceed the cumulative cessation cost in the 11th year and it will be 2.5 times 
in the 20th year; the cumulative medical cost plus productivity saving will exceed 
the cumulative cessation cost in the 7th year and it will be 3.4 times in the 20th 
year. ConClusions: Considering the attractive ROI results, it’s recommended that 
SC medicines should be covered in the SC intervention.
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SURvey
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objeCtives: To assess epinephrine auto-injector (EAI) availability and use for ana-
phylactic events in US schools during the 2013-2014 school year. Methods: This 
exploratory, cross-sectional, web-based survey analyzed anaphylactic events in eli-
gible schools participating in the Mylan-sponsored EpiPen4Schools® program, an 
ongoing initiative providing free EAIs and training to schools nationwide. Results: 
Survey participants consisted of 6019 of the > 40,000 schools in the EpiPen4Schools 
program. A total of 919 anaphylactic events were reported in 11% of schools (607/5683). 
Importantly, 22% of anaphylactic events (n= 187) occurred in individuals with no 
known allergies; most events (89%, 757/852) occurred in students. Of the 851 events 
with treatment information, 75% of individuals (n= 636) were administered epineph-
rine via an EAI, 49% (n= 310) of whom used the schools’ stock EAI provided through 
the EpiPen4Schools program (despite known prior allergies in 69% of anaphylactic 
cases). Of note was the disparity between the number of qualifying schools in the 
EpiPen4Schools program, nationwide, with Illinois having the highest (n= 2282) and 
District of Columbia the lowest (n= 4) number of participating schools. ConClusions: 
One in 10 schools participating in the survey reported ≥ 1 anaphylactic event during 
the 2013-2014 school year. Of those individuals treated with EAIs, nearly half used 
their school’s stock EAI, provided through the EpiPen4Schools program, suggesting 
the value of stocking EAIs for student/staff safety and potential cost savings. Studies 
on the cost of inpatient care for anaphylaxis indicate approximately $4700 per event. 
Furthermore, data suggest significantly higher treatment costs and poorer outcomes 
when treatment with an EAI is delayed. The prevalence of anaphylaxis continues to 
increase, as do the costs associated with receiving treatment and delaying or failing 
to receive treatment; removing barriers to access and increasing availability of treat-
ment is an important public health goal.
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ASSeSSment of diSeASe StAte Knowledge Among tb PAtientS in 
QUettA, PAKiStAn
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objeCtives: The study aimed to evaluate the level of disease state knowledge among 
tuberculosis patients. Methods: A questionnaire based cross-sectional study was car-
ried out among patients with TB in Fatima Jinnah chest hospital Quetta. Data was col-
lected by a pre-tested structured questionnaire that contain twenty two (22) regarding 
information related to TB (including etiology, symptoms, transmission, diagnosis and 
treatment). The descriptive statistics was used to present the data. Inferential statistics 
was used to the evaluation relationship among study variables. All analyses were per-
formed using SPSS 20.0. Results: Majority (60.0%) of the study patients were female 
and belong to age group of 22 to 31 years (24.28%). Majority (41.4%) of the respondents 
were illiterate and had received religious education(31.4%). The mean knowledge score 
was 11.23 ± 3.6 which is categorized as poor knowledge and posters/broachers and 
other printed material was reported as major source of information. No demographic 
characteristic was influencing the mean knowledge scores. ConClusions: The study 
concluded that the TB patients had poor disease state knowledge. Efforts should be 
made educate the patients regardless to the demographic characteristics, so that better 
disease control and further spread of infection would be prevented.
SenSoRy SyStemS diSoRdeRS – clinical outcomes Studies
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objeCtives: The presence of adverse events (AEs) associated with topical rosacea 
agents may lead to a lack of treatment adherence. Previous studies have reported 
low adherence rates among treated rosacea patients. This study describes the rate 
of treatment changes due to AEs and associated healthcare costs among rosacea 
patients receiving a topical therapy. Methods: Patients diagnosed with rosacea 
(ICD-9-CM: 695.3) who are newly initiating treatment with topical metronidazole, 
azelaic acid, sodium sulfacetamide/sulfur, benzoyl peroxide between 1/2009 and 
10/2013 were identified from MarketScan databases. Patients were required to 
be ≥ 30 years old, continuously eligible with medical and pharmacy benefits ≥ 12 
months pre- and ≥ 3 months post-treatment and without evidence of oral antibiotic 
or rosacea conjunctivitis during the study period. An AE was defined as a treatment 
switch within 2 weeks or medical claim with an AE diagnosis code. Persistence was 
defined as continuous refill of the index drug/formulation within 1.5 times the days’ 
supply of the prior prescription. Rate of AEs, treatment patterns, and healthcare 
costs were evaluated in the post-index period. Results: This analysis included 
49,351 patients. The mean age was 54 years and 25.5% were male. Metronidazole 
(72.7%) was the most common treatment and the predominant formulation was gel 
nificant differences were found in adherence across age groups (p= 0.34), genders 
(p= 0.43), or races (p= 0.62). ConClusions: Adherence to COPD maintenance medi-
cations was low among Medicare beneficiaries with COPD.
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exPenditUReS, oUt-of-PocKet SPending, dRUg UtilizAtion, And AcceSS 
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Bonakdar A.
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objeCtives: To measure the extent to which closing the coverage gap will affect drug 
utilization, access, and OOP spending among seniors with chronic diseases, includ-
ing respiratory diseases (asthma or COPD), hypertension, hyperlipidemia, psychosis, 
depression, and diabetes. Methods: A difference-in-difference-in-difference (DDD) 
analysis from 2008 to 2012 was used. Results: The Medical Expenditure Panel Survey 
data files from 2008 to 2012 imply that closing the coverage gap had no significant 
impact on the disparities in annual drug expenditures, OOP spending, and total num-
ber of prescriptions between minorities and whites. However, it significantly increased 
the disparity in access to prescriptions between minorities and whites by 3.8 percent. 
When teasing out the effect by race, the results show that closing the coverage gap 
had no significant impact on the disparities in OOP spending and total number of pre-
scriptions between African-Americans and whites, while it significantly increased the 
disparity in access to prescriptions for by 7.3 percent, and significantly decreased the 
disparity in annual drug expenditures by $1,162. Regarding Hispanics, it significantly 
increased the disparities in OOP spending and total number of prescription drugs by 
$325 and 8 prescriptions, respectively. However, it had no significant impact on the 
disparities in annual drug expenditures and access to prescriptions. ConClusions: 
The findings of this study demonstrate that the benefits of closing the coverage gap 
are disproportionately distributed among different racial groups. Closing the coverage 
gap decreased disparities in annual drug expenditures, OOP spending, and access to 
prescription drugs for African-American compared to white, while It increased dis-
parities in annual drug expenditures, OOP spending, and total number of prescription 
for Hispanics compared to whites.
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ReimbURSment And PReScRibing in exchAnge-bASed PlAnS: how 
doeS foRmUlARy geneRoSity diffeR fRom commeRciAl PlAnS And iS 
indicAtion A Key fActoR?
Moore R., Lewis C.
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objeCtives: Decisions regarding formulary generosity of exchange-based plans have 
undoubtedly affected uptake of specific therapies at a time of guaranteed-issue cover-
age and out-of-pocket maximums. This study examined formulary decisions made by 
managed care organizations for their exchange-based plans, and assessed the impact 
of these decisions on brand prescribing for asthma, bipolar disorder, and multiple 
sclerosis, to discern differences between indications. Methods: Surveys of 120 MCO 
pharmacy and medical directors, and 270 pulmonologists, psychiatrists, neurologists, 
and primary care physicians were conducted in 2014 and 2015 to determine formulary 
coverage on exchange-based plans, and the impact of this coverage on brand prescrib-
ing to patients covered by such plans. Results: Some 41% of surveyed MCOs reported 
the formularies of their exchange-based plan and largest commercial plan to be dis-
tinct; the exchange-based plans of 52% of these respondents covered fewer brands 
overall. Furthermore, increased tier 3+ (non-preferred) coverage and/or exclusion of 
some brands in/from their exchange-based plans versus their largest commercial plans 
were noted by an average of 8%, 10%, and 0% of MCOs for asthma, bipolar disorder, 
and multiple sclerosis drugs, respectively. In response, surveyed physicians reported 
decreased prescribing of specific drugs, particularly those competing versus generics, 
that were subject to less favorable/complete lack in exchange-based coverage versus 
traditional commercial coverage. The greatest impact of less favorable exchange-based 
plan coverage on uptake was on bipolar disorder, where, for example Seroquel XR 
was prescribed to 8% of exchange-based plan patients versus 5% of commercial plan 
patients. ConClusions: Less-generous reimbursement on exchange-based plans is 
evident, demonstrating desires by MCOs to limit costs on these plans. Consequently, 
there is increased prescribing of generics and preferred brands when available over 
higher-cost agents. Therapy areas with a number of cheaper options will be most 
affected, while specialty therapy areas will remain largely immune to this trend.
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RetURn on inveStment of SmoKing ceSSAtion benefit comPARiSon in 
gUAngdong, chinA
Liu D.1, Zhu S.2, Dong P.1
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objeCtives: Knowing the return-on-investment of smoking cessation (SC) is critical 
for policy makers to understand its economic benefit and implement effective SC 
intervention. The study sought to assess the return-on-investment (ROI) of smoking 
cessation in Guangdong, China and inform its economic benefit to policy mak-
ers. Methods: A decision tree model about ROI of SC benefit comparison was 
developed and adapted, which compared the costs, benefits and outcomes of 2 
SC benefit scenarios over 20-year time frame. The main difference between the 2 
scenarios was whether SC medicines were covered or not. Key inputs were obtained 
from available public sources, including smoking population, potential medical 
costs and savings along with productivity improvement, participants’ expected 
quit rates and relapses, etc. Results: If SC medicines are covered, the number 
of attempts and successes will increase 11 million and 1.3 million respectively 
in 20 years in Guangdong; the annual medical cost saving will exceed the annual 
cessation cost in the 6th year and it will be 7.7 times in the 20th year; the annual 
medial cost plus productivity saving will exceed the annual cessation cost in the 
4th year and it will be 9.5 times in the 20th year; the cumulative medical cost saving 
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according to Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality 
Index (DLQI) scores. Methods: All patients who stayed on the same active treat-
ment for 52 weeks were included. Active treatments were subcutaneous secuki-
numab 300 mg (n= 568) or 150 mg (n= 570) at weeks 0, 1, 2, 3, and 4, followed 
by dosing every 4 weeks, and subcutaneous etanercept 50 mg twice weekly for 
12 weeks and then once weekly (n= 323). Total AUCs over the 52-week period by 
percentage of PASI-75/90/100 and DLQI-0/1 (no impact on patient quality of life) 
responders—measuring overall controlled disease time—were determined using 
all responder numbers at all scheduled visits. Results: Total AUCs for patients 
who received secukinumab 300 and 150 mg, and etanercept, respectively, were: 
3857.8, 3286.9, and 2628.1 (PASI-75); 3017.7, 2212.2, and 1531.8 (PASI-90); 1677.0, 
978.9, and 452.5 (PASI-100); and 3029.8, 2492.2, and 1991.4 (DLQI-0/1). Total AUC 
ratios for secukinumab 300 and 150 mg, respectively, vs etanercept were 1.47 and 
1.25 (PASI-75); 1.97 and 1.44 (PASI-90); 3.71 and 2.16 (PASI-100); and 1.52 and 1.25 
(DLQI-0/1). Total AUC ratios for secukinumab 300 vs 150 mg were 1.17 (PASI-75), 
1.36 (PASI-90), 1.71 (PASI-100), and 1.22 (DLQI-0/1). ConClusions: In patients with 
moderate-severe plaque psoriasis, greater AUCs by PASI-75/90/100 and DLQI-0/1 
responders were achieved with secukinumab 300 mg, followed by secukinumab 
150 mg and etanercept. This analysis suggests that secukinumab 300 mg resulted 
in the best overall disease control over time.
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Knowledge And PRActice of PhARmAcy StUdentS RegARding the USe 
of SKin whitening PRodUct
Ab Hadi H., Awadh A.
International Islamic University Malaysia, Kuantan, Malaysia
objeCtives: The aim of this study was to assess the knowledge and practice 
of International Islamic University Malaysia (IIUM) Kuantan Undergraduate 
Pharmacy students on the use of skin whitening product. Methods: A self-
administered questionnaire on the use of skin whitening product was dis-
tributed to IIUM Kuantan Undergraduate Pharmacy students at IIUM Kuantan 
Malaysia. Results: Three hundred and nine (309) of four hundred (400) students 
responded (77% response rate). The highest percentage of participants is from 
year three students which is 33.3% while year four students are the least which 
is 18.8%. The mean of knowledge score, regardless of their year of study is 6.75 
over 14. Among the user and non-user of skin whitening products, user shows 
higher mean knowledge score which is 7.5041 than non-user which is 6.2527.Of 
the participants, 39.8% (123/309) are using the skin whitening products. 90.8% 
(108/119) of the respondent read the instruction of the products before using 
them. ConClusions: It is proven that the user of skin whitening products has 
better knowledge about the product than the non-user. Half of the participants 
are still practicing poor practice in using the skin whitening products. There is a 
need to educate the students about the proper usage of skin whitening products 
to avoid any misuse of these products.
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AntidePReSSAnt USe in PAtientS with Age-RelAted mAcUlAR 
degeneRAtion And dePReSSive SymPtomS: bASeline ReSUltS fRom the 
low viSion dePReSSion PRevention tRiAl
Pizzi L.T.1, Karel L.I.2, Shang T.1, Casten R.J.3, Rovner B.W.4
1Thomas Jefferson University, Philadelphia, PA, USA, 2Thomas Jefferson University Hospital, 
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objeCtives: Characterize baseline utilization of antidepressant and psychotropic 
medications in older adults with age-related macular degeneration (AMD) and 
depressive symptoms. Methods: Patients ≥ 65 years with bilateral AMD and 
subthreshold depressive symptoms were recruited from a large private retina 
practice affiliated with a tertiary eye care institution to participate in the Low 
Vision Depression Prevention Trial testing a multi-component intervention that 
combined low vision rehabilitation (LVR), home-based occupational therapy, and 
behavioral activation versus supportive therapy with LVR. Variables considered 
were age, sex, race, education, marital status, living situation, medical comorbid-
ity, depressive symptoms, and medication use. Medications of interest included 
prescription antidepressants and psychotropics. Depressive symptoms were meas-
ured using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 1 to 27, 
with higher scores indicating greater severity. Scores ≥ 5 indicate at least mild 
depression. Results: Of the 188 participants, 70% were female, 98% Caucasian, 
and the mean age was 84. The mean PHQ-9 score was 5.5 (SD 2.3), and 32% were 
taking at least one depression and/or psychotropic medication. For those reporting 
these medications, 47 (25%) reported 1 medication, 12 (6%) reported 2 medications, 
and one (0.05%) reported 3 medications. Participants with higher PHQ-9 scores 
were more likely to report ≥ 1 depression and/or psychotropic medication (p = 
0.001). No significant associations were found between use of these medications 
and demographic or medical variables with the exception of cardiovascular dis-
ease (p = 0.033). ConClusions: Individuals with AMD are at risk for depressive 
disorders due to the substantial impact vision loss has on quality of life. In this 
study, about one third of patients reported depression and/or psychotropic medi-
cation treatment. While this rate is higher than prior studies, findings suggest an 
opportunity to increase the number treated with medications and/or behavioral 
approaches.
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StUdy of PSychologicAl StReSS And Acne vUlgARiS Among PhARmAcy 
StUdentS
Ab Hadi H., Awadh A.
International Islamic University Malaysia, Kuantan, Malaysia
objeCtives: Acne vulgaris is described as a common skin disease involving block-
age and inflammation of pilosebaceous unit such as hair follicles and sebaceous 
gland. As many factors may contribute to the formation of acne, this study attempt 
(70.4%). Approximately 6,270 (12.7%) had a coded AE. Of the AE patients, 3.2% were 
persistent with treatment despite the AE, 7.4% switched to another treatment within 
8.8 days, and 89.4% discontinued therapy within 31.1 days. AE patients incurred $325 
(medical: $143, pharmacy: $182) in rosacea-related costs, while patients without AEs 
incurred $172 (medical: $14, pharmacy: $157). ConClusions: The majority of AEs 
associated with current rosacea drugs/formulations resulted in treatment switch/
discontinuation. New drug/formulation may provide additional treatment options 
for patients with AEs and lead to improved persistence and better symptom control.
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indiRect tReAtment comPARiSon of inteRventionS foR neovAScUlAR 
(wet) Age-RelAted mAcUlAR degeneRAtion (wet Amd)
Malcolm W.A.1, Hodgson R.2, Glanville J.2, Barata T.3, Fleetwood K.3
1Novartis UK, Frimley, UK, 2York Health Economics Consortium, York, UK, 3Quantics Consulting 
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objeCtives: To undertake a network meta-analysis (NMA) to assess the effective-
ness of licensed interventions (aflibercept 2q8, ranibizumab PRN, pegaptanib and 
photodynamic therapy (PDT)) in the treatment of neovascular (wet) age-related 
macular degeneration (wet AMD). Methods: A systematic review was undertaken 
to identify trials comparing any of the interventions to treat neovascular AMD 
reporting change in best corrected visual acuity (BCVA). A NMA of the studies was 
carried out using WinBugs. Identified studies often reported results at multiple time 
points. Hence, a number of models were applied accounting for the time structure 
in the data. The deviance information criterion (DIC) was used to select the most 
appropriate model. Multiple separate networks were applied to the data to account 
for the fact that posologies were equivalent at some time points. Results: 21 tri-
als were included in the network. Aflibercept and ranibizumab were found to be 
statistically superior to PDT and pegaptanib at 12 and 24 months. The mean change 
from baseline BVCA estimated between ranibizumab and PDT at 12 months was 
18.85 [15.42 to 22.26] and at 24 months was 20.62 [17.25 to 23.96]. The mean change 
from baseline BVCA estimated between ranibizumab and pegaptanib at 12 months 
was 11.16 [2.93, 20.63] and at 24 months was 11.71 [3.31, 25.06]. Results for afliber-
cept were quantitatively similar. There was minimal difference in the effectiveness 
of ranibizumab and aflibercept at any time point: mean difference at 12 months 
numerically favoured ranibizumab by 0.05 [-1.33 to 1.52] and at 24 months by 0.02 
[-1.36 to 1.44]. ConClusions: Aflibercept and ranibizumab are effective treatments 
for neovascular AMD demonstrating a clinically and statistically significant differ-
ence in BVCA compared with PDT and Pegaptanib. There were only minimal (non-
statistically significant) differences in the relative effectiveness of aflibercept and 
ranibizumab at any time point.
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comPARAtive effectiveneSS of bimAtoPRoSt 0.03%/timolol 0.5% 
PReSeRvAtive-fRee fixed combinAtion foR the tReAtment of oPen-
Angle glAUcomA And oht; inteRPReting ReSUltS fRom A lARge 
tReAtment netwoRK
Saunders O.1, Wong W.2, Collomb D.3, Stradwick S.1
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objeCtives: A network meta-analysis (NMA) evaluating the effectiveness of 
bimatoprost 0.03%/timolol 0.5% preservative-free (PF) fixed combination (PF 
BTFC) solution in single-dose vials for the treatment of glaucoma/ocular hyper-
tension (OHT) compared to alternative therapies has been updated (Harvey et 
al 2013). The outcome of interest was change from baseline (CFB) in intraocular 
pressure (IOP). Methods: Systematic searches originally conducted in October 
2012 were updated to identify additional randomized controlled trials investigat-
ing the efficacy of glaucoma/OHT therapies, where efficacy is defined as IOP CFB. 
A Bayesian model with random effects for trial, week and time of day was fitted 
to synthesize the resulting evidence base. Results: In total, 170 studies met 
the pre-determined mixed treatment comparison inclusion criteria, represent-
ing 34 unique treatment arms. PF BTFC was numerically superior to all treat-
ments (monotherapies and combination therapies; preserved and PF therapies) 
in lowering IOP and statistically significant (p< 0.05) for all but seven of the 33 
comparisons. Furthermore, despite some trials being adequately sized and the 
treatment effect showing similar levels of uncertainty to others in the network, 
the credible intervals (CI) for these treatments were among the widest in the 
network. ConClusions: PF BTFC was numerically but not statistically superior 
to all treatments in lowering IOP. The sample size required to show statistically 
significant results in NMAs is larger than for head-to-head randomized trials 
because the precision of comparisons made across a network is proportional not 
only to the size and uncertainty of individual trials but also to the number of nodes 
separating treatments (Thorlund 2012). This is thought to be a key driver of the 
width of CIs for some treatments within this network. Results from the updated 
NMA will be presented along with a discussion of the interpretation of results for 
large and complex networks.
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efficAcy of SecUKinUmAb in PAtientS with PlAQUe PSoRiASiS: AReA 
UndeR the cURve of tReAtment ReSPonSe RAteS
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objeCtives: Assessment of how therapies achieve cumulative disease control 
over time is critical. In two phase III, 52-week trials (ERASURE and FIXTURE), 
secukinumab—a human, anti–interleukin-17A, monoclonal antibody—was an 
effective treatment for moderate-severe chronic plaque psoriasis. Pooled analysis 
of these trials was performed to explore the cumulative efficacy of secukinumab 
by assessing area-under-the-curve (AUC) of percentage of treatment responders 
